Discovery of Aurora A/HDAC dual-target inhibitors: broad-spectrum in vitro antitumor activity and in vivo pharmacokinetic limitations.
Z20 is a potent Aurora A/HDAC dual-target inhibitor in vitro, while its pharmacokinetic defects limit clinical potential, which highlights the necessity of optimizing pharmacokinetic profiles for translating in vitro potency to in vivo efficacy.